FDA approves tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea

The FDA's December 20, 2024 approval of tirzepatide for moderate-to-severe obstructive sleep apnea in adults with obesity is the first approval of a GLP-1 class drug for OSA — a comorbidity that affects an estimated 25 million American adults.

What the SURMOUNT-OSA trials showed

Two parallel Phase 3 trials enrolled adults with moderate-to-severe OSA and BMI ≥30. Tirzepatide produced AHI (apnea-hypopnea index) reductions of 27 events/hour from a baseline of ~50 events/hour over 52 weeks — a clinically meaningful reduction that often moved patients from severe to mild OSA category.

Mechanism — weight-loss-mediated

The OSA reduction is mediated by weight loss, particularly visceral and upper-airway adipose. The mean weight loss in SURMOUNT-OSA arms was 18-20% — consistent with SURMOUNT-1 mean trajectory. Patients who did not lose weight did not show OSA improvement.

Practical implications

For patients with obesity-associated OSA, tirzepatide is now an FDA-labeled indication, opening insurance coverage pathways that didn't exist when prescribers were using GLP-1s off-label for OSA. CPAP remains first-line for confirmed OSA; tirzepatide is a complement, not a replacement.